Related Experiment Videos
Pseudohypopyon following intravitreal triamcinolone acetonide injection
Mithlesh C Sharma1, Wico W Lai, Michael J Shapiro
1Vitreoretina Service, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago Eye and Ear Infirmary, Chicago, IL 60612, USA. sharmamc@hotmail.com
Cornea
|April 21, 2004
Summary
A case report details pseudohypopyon, a benign condition, occurring after triamcinolone acetonide intravitreal injections for age-related macular degeneration. Early identification is key to differentiate it from true hypopyon, ensuring appropriate management.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacology
Background:
- Intravitreal triamcinolone acetonide is used to treat choroidal neovascularization in age-related macular degeneration.
- Pseudohypopyon is a rare complication that can occur after ocular procedures.
Observation:
- A 62-year-old woman developed a pseudohypopyon after receiving an intravitreal triamcinolone acetonide injection.
- Yellowish deposits were observed in the anterior chamber one day post-injection.
- The patient remained asymptomatic with no vision loss or ocular redness.
Findings:
- The observed anterior chamber deposits resolved spontaneously within four days.
- This presentation was consistent with a pseudohypopyon, not an infectious or inflammatory hypopyon.
Implications:
- Clinicians must be aware of pseudohypopyon as a potential adverse event following triamcinolone acetonide injections.
- Accurate differentiation between pseudohypopyon and true hypopyon is crucial for appropriate patient management and prognosis.
- This distinction avoids unnecessary aggressive treatments for a self-limiting condition.